In older patients with permanent AF and HF, digoxin and bisoprolol did not differ for QoL at 6 mo
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Digoxin and bisoprolol showed similar effects on quality of life for patients with atrial fibrillation. Neither drug significantly improved patient-reported outcomes in this randomized trial.
Area Of Science
- Cardiology
- Clinical Trials
- Pharmacology
Background
- Atrial fibrillation is a common arrhythmia affecting heart rate control.
- Patient-reported quality of life is a crucial outcome in managing chronic conditions.
- Previous studies have not definitively compared digoxin and bisoprolol for quality of life in atrial fibrillation.
Purpose Of The Study
- To compare the efficacy of digoxin versus bisoprolol in controlling heart rate in patients with atrial fibrillation.
- To assess the impact of digoxin and bisoprolol on patient-reported quality of life.
Main Methods
- The RATE-AF trial was a randomized clinical trial.
- Participants with atrial fibrillation were randomized to receive either digoxin or bisoprolol.
- Quality of life was measured using patient-reported outcome instruments.
Main Results
- No significant difference in quality of life was observed between the digoxin and bisoprolol groups.
- Both medications were effective in heart rate control for atrial fibrillation.
- Patient-reported outcomes did not favor one drug over the other.
Conclusions
- Digoxin and bisoprolol offer comparable quality of life benefits for patients with atrial fibrillation.
- Heart rate control strategies in atrial fibrillation should consider patient-reported outcomes.
- Further research may explore other patient-centered endpoints.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...